DE69219600D1 - Pharmazeutischer träger - Google Patents

Pharmazeutischer träger

Info

Publication number
DE69219600D1
DE69219600D1 DE69219600T DE69219600T DE69219600D1 DE 69219600 D1 DE69219600 D1 DE 69219600D1 DE 69219600 T DE69219600 T DE 69219600T DE 69219600 T DE69219600 T DE 69219600T DE 69219600 D1 DE69219600 D1 DE 69219600D1
Authority
DE
Germany
Prior art keywords
giving
matrix
inert
active substance
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69219600T
Other languages
English (en)
Other versions
DE69219600T2 (de
Inventor
Bror Morein
Karin Loevgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of DE69219600D1 publication Critical patent/DE69219600D1/de
Publication of DE69219600T2 publication Critical patent/DE69219600T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
DE69219600T 1991-05-31 1992-06-01 Pharmazeutischer träger Expired - Fee Related DE69219600T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101665A SE502569C2 (sv) 1991-05-31 1991-05-31 Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
PCT/SE1992/000367 WO1992021331A1 (en) 1991-05-31 1992-06-01 Pharmaceutical carrier

Publications (2)

Publication Number Publication Date
DE69219600D1 true DE69219600D1 (de) 1997-06-12
DE69219600T2 DE69219600T2 (de) 1997-10-02

Family

ID=20382906

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69219600T Expired - Fee Related DE69219600T2 (de) 1991-05-31 1992-06-01 Pharmazeutischer träger

Country Status (13)

Country Link
US (1) US5603958A (de)
EP (1) EP0587659B1 (de)
JP (1) JPH07500084A (de)
KR (1) KR100227302B1 (de)
AT (1) ATE152620T1 (de)
AU (1) AU680807B2 (de)
CA (1) CA2103447C (de)
DE (1) DE69219600T2 (de)
ES (1) ES2103946T3 (de)
FI (1) FI110408B (de)
NO (1) NO306539B1 (de)
SE (1) SE502569C2 (de)
WO (1) WO1992021331A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP1304041B8 (de) * 1996-07-08 2005-06-01 Idemitsu Kosan Co., Ltd. Geflügelfutterzusammensetzung
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
WO2000021490A1 (de) * 1998-10-14 2000-04-20 Cognis Deutschland Gmbh Verwendung von nanoskaligen sterolen und sterolestern
HUP0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
NZ529347A (en) * 2001-04-04 2008-01-31 Nordic Vaccine Technology As Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7176237B2 (en) * 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
DK1545605T3 (da) * 2002-10-02 2010-04-12 Nordic Vaccine As Komposition til vaccination
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP2371362B1 (de) 2004-01-22 2020-07-01 University of Miami Coenzym-Q10-Formulierungen zur Behandlung von soliden Tumoren durch intravenöse Gabe
CN100339083C (zh) * 2004-02-24 2007-09-26 范敏华 一种黄体酮液体胶囊及其制备方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100398151C (zh) * 2005-02-18 2008-07-02 浙江大学 人参皂甙纳米微粒及其制备方法和用途
US20110098177A1 (en) * 2006-03-28 2011-04-28 Novus International Inc. Methods and compositions of plant micronutrients
US8691843B2 (en) * 2006-07-12 2014-04-08 Novus International, Inc. Antioxidant combinations for use in ruminant feed rations
US20080015218A1 (en) * 2006-07-12 2008-01-17 Novus International Inc. Antioxidant combinations for use in ruminant feed rations having a fat source
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
MX2009005228A (es) * 2006-11-17 2009-05-28 Novus Int Inc Composiciones incrustadas en matriz que tienen acidos organicos y acidos grasos.
EP2094651A1 (de) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthese und biologische wirkungen neuer tricyclischer bis-enone (tbes)
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
US20080119552A1 (en) * 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
EP2136787B1 (de) 2007-03-22 2019-08-21 Berg LLC Topische formulierungen mit erhöhter bioverfügbarkeit
EP2161986A4 (de) * 2007-07-03 2014-06-25 Novus Int Inc Futterrationen für ferkel mit niedrigem anteil an fermentierbaren kohlenhydraten
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
WO2009088879A1 (en) * 2008-01-04 2009-07-16 Novus International Inc. Combinations to improve animal health and performance
CA2711834C (en) * 2008-01-11 2017-03-14 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
BRPI0911658A2 (pt) 2008-04-11 2015-10-13 Cytotech Labs Llc métodos e usos de indução de apoptose em células de câncer
TWI453023B (zh) 2008-04-18 2014-09-21 Reata Pharmaceuticals Inc 抗氧化發炎調節劑：在ｃ－１７處具有胺基及其他修飾之齊墩果酸衍生物
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EP2271658B1 (de) * 2008-04-18 2016-11-09 Reata Pharmaceuticals, Inc. Antioxidationsmittel als entzündungsmodulierende substanzen: c-17-homologierte oleanolsäurederivate
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
CA2731650A1 (en) * 2008-07-22 2010-01-28 Tadashi Honda Monocyclic cyanoenones and methods of use thereof
EP2429512A4 (de) 2009-05-11 2013-07-31 Berg Pharma Llc Verfahren zur behandlung von stoffwechselerkrankungen mit epimetabolischen shiftern, mehrdimensionalen intrazellularen molekülen oder umgebungsbeeinflussern
US20110020914A1 (en) * 2009-07-24 2011-01-27 Novus International Inc Methods for enhancing growth of organisms in an aqueous growth medium
US11400058B2 (en) * 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
RS57350B1 (sr) 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
EP3730131A1 (de) 2013-09-04 2020-10-28 Berg LLC Verfahren zur behandlung von krebs mittels kontinuierlicher infusion von coenzym q10
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0231039B1 (de) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
US5196192A (en) * 1988-05-31 1993-03-23 Biotechnology Australia Pty. Ltd. Actions of hormones
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5077057A (en) * 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity

Also Published As

Publication number Publication date
DE69219600T2 (de) 1997-10-02
SE9101665L (sv) 1992-12-01
CA2103447A1 (en) 1992-12-01
JPH07500084A (ja) 1995-01-05
AU680807B2 (en) 1997-08-14
ATE152620T1 (de) 1997-05-15
ES2103946T3 (es) 1997-10-01
NO934315L (no) 1994-01-26
KR100227302B1 (ko) 1999-11-01
AU1925192A (en) 1993-01-08
FI110408B (fi) 2003-01-31
WO1992021331A1 (en) 1992-12-10
FI935314A0 (fi) 1993-11-29
NO934315D0 (no) 1993-11-29
CA2103447C (en) 1999-03-16
NO306539B1 (no) 1999-11-22
SE502569C2 (sv) 1995-11-13
EP0587659B1 (de) 1997-05-07
FI935314A (fi) 1993-11-29
SE9101665D0 (sv) 1991-05-31
EP0587659A1 (de) 1994-03-23
US5603958A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
DE69219600D1 (de) Pharmazeutischer träger
ES2243229T3 (es) Formulaciones de particulas de hidrogel.
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
MY118371A (en) Tetrahydrolipstatin containing compositions
CA2231195A1 (en) Sustained release matrix for high-dose insoluble drugs
ATE55243T1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
HUP0104230A2 (hu) Eljárás inhalációs adagolásra alkalmas hatóanyagszemcsék szuszpenzióinak előállítására
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
NO974404L (no) Insufflasjonsbærer for medikamenter med kontrollert frigivelse
IL138767A0 (en) Anticancer compositions
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
CA2119253A1 (en) Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres-SLN)
ATE229796T1 (de) Mittel zur antitumortherapie
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
IL152074A0 (en) Pharmaceutical preparations and their manufacture
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
RU94016184A (ru) Противоаллергическая композиция для местного глазного применения, способ ее получения
DE69222295T2 (de) Pulverförmige pharmazeutische Zusammensetzung
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
DE69717279T2 (de) Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen
AR017760A1 (es) Una forma de dosificacion transdermica que comprende un androgeno no reducible en 5-alfa
MX9706412A (es) Uso de aerogeles inorganicos en la industria farmaceutica.
BR0008065A (pt) Derivados de colestano insaturados e seu uso para a preparação de medicamentos que regulam meiose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BTG INTERNATIONAL LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee